Background
A prospective, observational study was initiated in 2009 with IRB approval to track outcomes and determine the clinical utility of multi-platform molecular profiling (MMP) across a variety of solid tumors. A secondary objective was to assess the impact of MMP on physicians’ treatment decisions.